000			03306nam a2200289 4500
001			ESSALUD
005			20260821125939.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aLe Roux, Carel W. _eAutor _954269
245			_aSurvodutide once weekly for the treatment of adults with obesity
300			_apáginas: 776-787
520			_aBackground: Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain. Survodutide, an investigational glucagon receptor–GLP-1 receptor dual agonist, led to substantial weight reduction in a phase 2 trial involving adults with obesity without diabetes. Methods: In this phase 3, double-blind trial, we randomly assigned adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher, or 27 or higher with at least one obesity-related complication (excluding diabetes), in a 1:1:1 ratio to receive once-weekly survodutide administered subcutaneously at a dose adjusted up to 3.6 mg or 6.0 mg or placebo, in addition to counseling for lifestyle modification. The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76. The primary efficacy analysis was conducted according to the treatment-regimen estimand, which incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and a prolonged dose-escalation period. Results: Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men. At baseline, the mean BMI was 37.9, and the mean body weight was 108.8 kg. At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was –12.2% (95% confidence interval [CI], −13.6 to −10.8) in the 3.6-mg group, –13.0% (95% CI, −14.4 to −11.6) in the 6.0-mg group, and –5.4% (95% CI, −6.9 to −4.0) in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo). The most common adverse events were gastrointestinal symptoms (typically mild to moderate), which occurred in 80.9% of the participants in the 3.6-mg group, in 89.7% of those in the 6.0-mg group, and in 47.9% of those in the placebo group. No deaths were reported. Conclusions: Survodutide led to significantly greater reductions in body weight than placebo in adults with obesity without diabetes.
650			_aCARDIOLOGÍA GENERAL _953638
650			_aMEDICINA CLÍNICA GENERAL _953666
650			_aENDOCRINOLOGÍA GENERAL _954270
650			_aHIPERTENSIÓN
650			_aOBESIDAD _91238
700			_aWharton, Sean _954271
700			_aStartseva, Elena _954272
700			_aKloer, Isabel M. _954273
700			_aAjaz Hussain, Samina _954274
773	0		_022717 _922650 _dMassachusetts NEJM Group _oNEJM12 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-21 _zsqb
999			_c22855 _d22855